NCT07345260 The Effects of a Nutritional Supplement on Sleep Quality
| NCT ID | NCT07345260 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Athletic Greens International |
| Condition | Sleep |
| Study Type | INTERVENTIONAL |
| Enrollment | 140 participants |
| Start Date | 2026-01-02 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 140 participants in total. It began in 2026-01-02 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a randomized, double-blind, placebo-controlled study of N=140 adult men and women with sub-clinical sleep issues. This study to assess the effect of a novel dietary supplement on sleep related outcomes.
Eligibility Criteria
Inclusion Criteria: 1. Be male or female 2. Be aged 35-65. 3. Body Mass Index: ≥18.5 and ≤29.9 kg/m2 4. Anyone currently experiencing issues with falling asleep, staying asleep, or waking up during the night 5. Score of 7 or less on the RU-SATED validated sleep questionnaire. 6. Anyone willing to follow the study protocol. 7. Anyone willing to discontinue any other supplements (nootroptics, adaptogens, calming herbs), medications, herbal remedies, over the counter sleep medications \[e.g., zolipidem, diphenhydramine (Benadryl or unisom), magnesium or melatonin products\] used to assist with sleep for the duration of the study. 8. Agree to limit alcohol intake within \~4 hours of bedtime 9. Agree to limit caffeine intake to ≤ 400 mg/day (\~3-4 cups of coffee) or ingestion of caffeine-containing products after 2:00 PM during the study period. 10. Anyone who is generally healthy - does not live with any uncontrolled chronic disease. 11. Resides in the United States. Exclusion Criteria: 1. Anyone with a diagnosed chronic sleep condition, including but not limited to insomnia, narcolepsy, REM Behavior Disorder, moderate to severe restless leg syndrome (RLS), or sleep apnea. 2. Women currently undergoing perimenopause or experiencing vasomotor symptoms such as night sweats. 3. Use of hormone therapy (including estrogen, progesterone, or phytoestrogens) within the last 3 months. 4. Anyone with diagnosed psychiatric disorders including major depressive disorder with acute symptoms, Bipolar disorder, Generalized anxiety disorder with active symptoms, PTSD with frequent nightmares 5. Anyone with diagnosed neurogenitive diseases or chronic pain disorders including Parkinson's disease, Alzheimer's disease, or uncontrolled fibromyalgia 6. Anyone who regularly consumes prescribed stimulant medications including Amphetamines (e.g., Adderall, Vyvanse), Methylphenidate (e.g., Ritalin, Concerta), and Modafinil / Armodafinil 7. Anyone currently on CNS activating anti-depressants including Bupropion (Wellbutrin), Fluoxetine, Venlafaxine (Effexor), Sertraline (Zoloft). 8. Current or recent use of cannabis or THC-containing products, including recreational or medicinal marijuana, CBD products with measurable THC content, or synthetic cannabinoids, within the past 30 days. 9. Anyone with a job that disrupts their nighttime sleep (e.g., excessive travel, night/3rd shift workers). 10. Anyone unwilling to wear the Oura ring device for the duration of the trial or unwilling to open the Oura application at least three times each week during the trial for data to sync to the cloud 11. Anyone currently taking a prescription sleep aid. 12. Anyone who introduces any new supplements, medications, herbal remedies, or melatonin products used to assist with sleep for the duration of the study. 13. Anyone with any allergies or sensitivities to any of the study product ingredients. 14. Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period). 15. Anyone with a history of substance abuse. 16. Anyone who drinks heavily (i.e., 8 or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men). 17. Currently partaking in another research study or will be partaking in any other research study for the next 7 weeks, or at any point during this study's duration.
Contact & Investigator
Ellen O'Gorman
PRINCIPAL INVESTIGATOR
Citruslabs
Frequently Asked Questions
Who can join the NCT07345260 clinical trial?
This trial is open to participants of all sexes, aged 35 Years or older, up to 65 Years, studying Sleep. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07345260 currently recruiting?
Yes, NCT07345260 is actively recruiting participants. Contact the research team at ellen@citruslabs.com for enrollment information.
Where is the NCT07345260 trial being conducted?
This trial is being conducted at Santa Monica, United States.
Who is sponsoring the NCT07345260 clinical trial?
NCT07345260 is sponsored by Athletic Greens International. The principal investigator is Ellen O'Gorman at Citruslabs. The trial plans to enroll 140 participants.